Reclast approved for fracture prevention

The FDA has approved Reclast (zoledronic acid injection, from Novartis) for the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The approval was based on a clinical trial which showed that once-yearly Reclast reduced the risk of new clinical fractures by 35% and new spine fractures by 46% compared to placebo.

Reclast is already indicated for the treatment of postmenopausal osteoporosis and Paget’s disease of the bone.

For more information call (888) NOW-NOVA or visit